85 Effect of COVID vaccination on monthly migraine days 4 of vaccination or insufficient compliance surrounding the vaccination dates, resulting in a representative group of n = 147 migraine patients with a combined total of 536 months of E-diary data (supplementary Figure 2). The mean age of responders to the questionnaire was 50.2 years and 81.3% were female. Baseline characteristics of the responders and those participants included in the infection or vaccination analysis are shown in Table 1. Of the 147 individuals in the vaccination group, the majority received solely one or more mRNA vaccines (73%), 16 participants (11%) exclusively received viral vector vaccines and 23 subjects (16%) received at least one vaccine of both types (supplementary Table 1). Table 1. Baseline characteristics of responders, included participants in the COVID infection analysis and included participants in the COVID vaccination analysis. Responders (N=336) Infection (N=59) Vaccination (N=147) Age, mean (SD) 50.2 (11.9) 47.8 (12.8) 50.3 (11.6) Female sex, n (%) 273 (81.3) 51 (86.4) 118 (80.3) BMI, mean (SD) 24.8 (4.2) 24.2 (3.4) 25.0 (4.4) Migraine without aura, n (%) 215 (64.0) 42 (71.2) 99 (67.3) Chronic migraine, n (%) 45 (13.4) 8 (13.6) 18 (12.2) Monthly migraine days, mean (SD) 6.9 (4.4) 6.7 (4.9) 6.0 (4.5) Monthly headache days, mean (SD) 10.6 (6.2) 9.2 (6.5) 9.0 (6.4) Monthly acute medication days, mean (SD) 4.9 (2.6) 4.3 (3.1) 4.2 (2.6) Patients self-reported perception Data were collected through a one-time questionnaire from a total of 336 participants. Among the respondents, 164 patients (49%) with migraine reported a history of COVID-19 infection. Of these patients, 64.6% (n = 106/164) reported to have precepted no change in MMD, whereas 26.2% (n = 43) perceived an increase, 1.2% (n = 2) perceived a decrease and 7.9% (n = 13) were uncertain about this. Regarding COVID-19 vaccination, 272 out of 336 (81%) patients with migraine reported having received a COVID-19 vaccine. Among them, 72.4% (n = 197) reported to have perceived no noticeable change in MMD, 12.9% (n = 35) perceived an increase, 3.7% (n = 10) perceived a decrease and 11.0% (n = 30) were uncertain. Effect of COVID-19 infection After correction for confounders, no difference in MMD was found in the first month (0.08; 95% confidence interval [CI] = –0.84 to 0.99; p = 0.983) after infection compared to the baseline MMD (Figure 1a). We also did not find a difference in MHD
RkJQdWJsaXNoZXIy MjY0ODMw